World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
116
Citations
53930
World Ranking
4331
National Ranking
236

Dieter Hoelzer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dieter Hoelzer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 857 publications — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dieter Hoelzer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dieter Hoelzer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 116 D-Index — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Dieter Hoelzer is affiliated with Goethe University Frankfurt in Germany and has contributed significantly to research in the field of medicine, with a particular focus on hematology and related subfields. Their scholarly work spans public health, environmental and occupational health, pediatrics, perinatology, child health, pathology, forensic medicine, and pulmonary and respiratory medicine.

Their research topics concentrate on various aspects of blood cancers and their treatments, notably acute lymphoblastic leukemia (ALL), chronic myeloid leukemia, lymphoma diagnosis and treatment, CAR-T cell therapy, hematopoietic stem cell transplantation, and acute myeloid leukemia.

Recent notable publications include:

  • Management of ALL in adults: 2024 ELN recommendations from a European expert panel, 2024, Blood
  • Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel, 2024, Blood
  • Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion, 2020, ESMO Open
  • Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial, 2020, Hematological Oncology
  • Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review, 2023, Leukemia & lymphoma/Leukemia and lymphoma

Their frequent co-authors include:

  • Nicola Gökbuget
  • Josep-María Ribera
  • Hagop M. Kantarjian
  • Pierre Fenaux
  • Nicolas Boissel

They have published extensively in several prominent journals, with frequent appearances in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia
  • ESMO Open
  • Hematological Oncology

Their body of work includes 35 publications categorized under medicine, with 10 focusing on hematology and an equivalent number addressing public health and occupational health. Research in pediatrics, perinatology, and child health accounts for 5 publications, while pathology, forensic medicine, and pulmonary and respiratory medicine are also represented. The main research topics show a strong emphasis on acute lymphoblastic leukemia research and chronic myeloid leukemia treatments, each with a substantial number of published works.

Best Publications

  • Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)

    Birgit Assmus;Volker Schächinger;Claudius Teupe;Martina Britten

  • Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

    Mathias J Rummel;Norbert Niederle;Georg Maschmeyer;G Andre Banat

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

    Marion G Ott;Manfred Schmidt;Kerstin Schwarzwaelder;Stefan Stein

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease

    Stefan Stein;Marion G. Ott;Stephan Schultze-Strasser;Anna Jauch

  • Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults

    D Hoelzer;E Thiel;H Loffler;T Buchner

  • A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

    Oliver G. Ottmann;Brian J. Druker;Charles L. Sawyers;John M. Goldman

  • Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

    Monika Brüggemann;Thorsten Raff;Thomas Flohr;Nicola Gökbuget

  • Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

    Matthias Klinger;Christian Brandl;Gerhard Zugmaier;Youssef Hijazi

  • Modern Therapy of Acute Lymphoblastic Leukemia

    Renato Bassan;Dieter Hoelzer

  • Treatment of Adult Acute Lymphoblastic Leukemia

    Nicola Gökbuget;Dieter Hoelzer

  • Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

    Mathias J. Rummel;Salah E. Al-Batran;Soo-Z. Kim;Manfred Welslau

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

    Nicola Gökbuget;Michael Kneba;Thorsten Raff;Heiko Trautmann

  • Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

    Nicola Gökbuget;Daniel Stanze;Joachim Beck;Helmut Diedrich

  • Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

    Felicitas Thol;Frederik Damm;Andrea Lüdeking;Claudia Winschel

  • Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

    Barbara Wassmann;Heike Pfeifer;Nicola Goekbuget;Dietrich W. Beelen

  • High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome

    Lothar Bergmann;Cornelius Miething;Ulrich Maurer;Jürgen Brieger

  • Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

    M. Bruggemann;A. Schrauder;T. Raff;H. Pfeifer

Frequent Co-Authors

Oliver G. Ottmann
Oliver G. Ottmann Cardiff University
Eckhard Thiel
Eckhard Thiel Charité - University Medicine Berlin
Arnold Ganser
Arnold Ganser Hannover Medical School
Hubert Serve
Hubert Serve Goethe University Frankfurt
Michael Kneba
Michael Kneba Kiel University
Michael Lübbert
Michael Lübbert University of Freiburg
Reinhard Seger
Reinhard Seger University of Zurich
Hervé Dombret
Hervé Dombret Université Paris Cité
Josep-Maria Ribera
Josep-Maria Ribera Autonomous University of Barcelona
Lothar Kanz
Lothar Kanz University of Tübingen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, there are several related online degrees and career pathways that can accelerate your entry into healthcare. For experienced nurses aiming to advance, exploring dnp online programs can open opportunities in leadership and specialized clinical roles. Many of these programs offer flexible schedules and competitive durations, making it easier to balance work and study.

For those seeking more streamlined options, there are dnp programs without dissertation, allowing students to complete degree requirements without the extensive research commitment typically needed for traditional doctoral programs. Newcomers to nursing might be interested in the fast track lpn route, which provides essential training in a shorter time frame to quickly start working as a licensed practical nurse.

Another in-demand specialization is mental health. With online psych np programs, registered nurses can efficiently gain advanced skills to support mental health needs, a growing priority in healthcare today.

Best Scientists Citing Dieter Hoelzer

Trending Scientists

Recently Published Articles